ទំព័រដើម › មហារីកកោសិកាស្រអាប់នៅក្បាល និងបំបៅក › ម៉ាសាឈូសេត › Boston
ការសាកល្បងគ្លីនិកសម្រាប់ មហារីកកោសិកាស្រអាប់នៅក្បាល និងបំបៅក នៅក្នុង Boston, MA
ការសិក្សាចំនួន 40 សម្រាប់ មហារីកកោសិកាស្រអាប់នៅក្បាល និងបំបៅក កំពុងរកអ្នកចូលរួមនៅតាមទីតាំងក្នុង និងជុំវិញ Boston (ក្នុងចម្ងាយប្រហែល 30 ម៉ាយ)។ បើកការសិក្សាមួយដើម្បីមើលថាតើនរណាអាចចូលរួម និងរបៀបទំនាក់ទំនងទៅកាន់ក្រុមការងារសិក្សា។
អត្ថបទសិក្សាផ្លូវការ (អង់គ្លេស)
កំពុងរកអ្នកចូលរួមសម្រាប់ការសិក្សាមួយនៅទីនេះ? លេចធ្លោនៅផ្នែកខាងលើនៃទំព័រនេះ — $99 សម្រាប់ 30 ថ្ងៃ →
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1
- Massachusetts General Hospital, Boston
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
កំពុងជ្រើសរើសដំណាក់កាល 2/3
- Site #0131, Boston
- Site#0101, Boston
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1
- Exelixis Clinical Site #7, Boston
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
កំពុងជ្រើសរើសដំណាក់កាល 3
- Boston Medical Center, Boston
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
កំពុងជ្រើសរើសដំណាក់កាល 1
- Research Site, Boston
- Research Site, Boston
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
កំពុងជ្រើសរើសដំណាក់កាល 3
- Dana Farber Cancer Institute, Boston
A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Dana Farber Cancer Institute, Boston
JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC
កំពុងជ្រើសរើសដំណាក់កាល 3
- Boston Medical Center, Boston
A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma
កំពុងជ្រើសរើសដំណាក់កាល 1
- Boston Medical Center, Boston
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Tufts Medical Center, Boston
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
កំពុងជ្រើសរើសដំណាក់កាល 2
- Tufts Medical Center, Boston
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Massachusetts General Hospital, Boston
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
កំពុងជ្រើសរើសដំណាក់កាល 2
- Tufts Medical Center, Boston
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours
កំពុងជ្រើសរើសដំណាក់កាល 1
- Massachusetts General Hospital, Boston
A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)
កំពុងជ្រើសរើសការសិក្សាសង្កេត
- Dana Farber Cancer Institute, Boston
PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC
កំពុងជ្រើសរើសដំណាក់កាល 2
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1
- Normunity Investigational Site, Boston
- Normunity Investigational Site, Boston
Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
កំពុងជ្រើសរើសដំណាក់កាល 2
- Boston Medical Center, Boston
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Massachusetts General Hospital - Dana Farber, Boston
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
កំពុងជ្រើសរើសដំណាក់កាល 1
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
PDT For Induction Therapy For Head And Neck Cancer
កំពុងជ្រើសរើសដំណាក់កាល 2
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1
- Massachusetts General Hospital, Boston
- Brigham & Women's Hospital, Boston
- Beth Israel Deaconess Medical Center,East Campus Research Pharmacy, Boston
- និង 2 ទៀត
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Preoperative Pembrolizumab and Chemotherapy in Resectable, Recurrent HNSCC
កំពុងជ្រើសរើសដំណាក់កាល 2
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1
- Beth Israel Deaconess Medical Center /ID# 252009, Boston
- Dana-Farber Cancer Institute /ID# 249642, Boston
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
កំពុងជ្រើសរើសដំណាក់កាល 3
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Dana-Farber Cancer Institute, Boston
This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1
- Dana Farber Cancer Institute, Boston
Neoadjuvant Ficerafusp Alfa With Pembrolizumab in Resectable SCC
កំពុងជ្រើសរើសដំណាក់កាល 2
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Drug Screening Using Novel IMD in Salivary and Head and Neck Cancers
កំពុងជ្រើសរើសដំណាក់កាលដំបូង ១
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Dana Farber Cancer Institute, Boston
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1
- Dana Farber/Partners Cancer Care Inc, Boston
Measurable Residual Disease Detection Using Tumor-Informed ctDNA Surveillance After Curative-Intent Treatment in HPV-Independent Squamous Cell Carcinoma of the Head and Neck
កំពុងជ្រើសរើសការសិក្សាសង្កេត
- Massachusetts Eye and Ear, Boston
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Massachusetts General Hospital, Boston
Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors
កំពុងជ្រើសរើសដំណាក់កាល 2
- Dana Farber Cancer Institute, Boston
ការសាកល្បងសម្រាប់ មហារីកកោសិកាស្រអាប់នៅក្បាល និងបំបៅក នៅក្នុងទីក្រុងផ្សេងទៀត
- Houston, TXការសិក្សា 47
- Los Angeles, CAការសិក្សា 42
- New York City, NYការសិក្សា 39
- Nashville, TNការសិក្សា 39
- St. Louis, MOការសិក្សា 28
- Arlington, VAការសិក្សា 26
- Philadelphia, PAការសិក្សា 26
- Chicago, ILការសិក្សា 26
- Atlanta, GAការសិក្សា 24
- San Antonio, TXការសិក្សា 22
- New Haven, CTការសិក្សា 22
- Pittsburgh, PAការសិក្សា 22
ការសិក្សាផ្សេងទៀតនៅក្នុង Boston
- មហារីកទ្រូងការសិក្សា 112
- Non-Small Cell Lung Cancerការសិក្សា 90
- មហារីក (គ្រប់ប្រភេទ)ការសិក្សា 85
- មហារីកដែលរីករាលដាលការសិក្សា 63
- មហារីកពោះវៀនធំ និងទ្វារមាសការសិក្សា 63
- មហារីកសួតការសិក្សា 62
- មហារីកស៊ុតការសិក្សា 61
- មហារីកតូចការសិក្សា 59
- ភាពសោកសៅការសិក្សា 52
- មហារីកស្រទាប់ស្បែកស្តីការសិក្សា 50
- បេះដូងខ្សោយការសិក្សា 44
- ជំងឺលីកូសេមីមីអេឡូអ៊ីដបន្ទាន់ការសិក្សា 44
ពី ClinicalTrials.gov, ទិន្នន័យទទួលបាននៅថ្ងៃ 6 តុលា 2026។ ការសិក្នានីមួយៗកំណត់លក្ខខណ្ឌលក្ខណៈសម្បត្តិរបស់ខ្លួន; ក្រុមការងារសិក្សាកំណត់ថាតើនរណាអាចចូលរួម។